A meta-analysis demonstrated that LDL cholesterol lowering by 40 mg/dl (1.04 mmol/l) resulted in a 23% decrease in CAD mortality [18]; therefore, lipid control is an unmet need that may be improved by the use of the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab. This evidence concerns the gene PCSK9 and coronary artery disorder.